Century Therapeutics Inc

NASDAQ IPSC

Data sourced from

and

Download Data

Century Therapeutics Inc Net Current Asset Value 2 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: -65.78%

Century Therapeutics Inc Net Current Asset Value 2 year CAGR is -65.78% for the Trailing 12 Months (TTM) ending March 31, 2024. Net current asset value is a financial metric that represents the excess of a company's current assets over its total liabilities. It is calculated by subtracting the total liabilities from the total current assets of a company. Net current asset value provides insights into the value that would be available to shareholders if the company were to liquidate its current assets and pay off its liabilities. This metric is used to assess the company's liquidity position and the potential value for shareholders in a liquidation scenario. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Century Therapeutics Inc Net Current Asset Value for the Trailing 12 Months (TTM) ending March 31, 2023 was 150,513,000.00, a -39.61% change year over year.
Century Therapeutics Inc Net Current Asset Value for the Trailing 12 Months (TTM) ending March 31, 2022 was 249,218,500.00, a 252.57% change year over year.
Century Therapeutics Inc Net Current Asset Value for the Trailing 12 Months (TTM) ending March 31, 2021 was -163,352,000.00.

NASDAQ: IPSC

Century Therapeutics Inc

CEO	Dr. Osvaldo Flores Ph.D.
IPO Date	June 18, 2021
Location	United States
Headquarters	3675 Market Street, Philadelphia, PA, United States, 19104
Employees	152
Sector	Healthcare
Industry	Biotechnology

Description

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Key trends